Back to Search Start Over

Effects of novel capsinoid treatment on fatness and energy metabolism in humans: possible pharmacogenetic implications

Authors :
Snitker, Soren
Fujishima, Yoshiyuki
Shen, Haiqing
Ott, Sandy
Pi-Sunyer, Xavier
Furuhata, Yasufumi
Sato, Hitoshi
Takahashi, Michio
Source :
American Journal of Clinical Nutrition. Jan, 2009, Vol. 89 Issue 1, p45, 6 p.
Publication Year :
2009

Abstract

Background: Capsinoids from the Capsicum genus of plants are nonpungent capsaicin-related substances with effects on metabolism and body weight in animals. Objectives: Our objectives were to explore the safety and efficacy of capsinoids taken orally (6 mg/d) for weight loss, fat loss, and change in metabolism and to examine whether candidate genes are predictors of capsinoid response. Design: This was a 12-wk, placebo-controlled, double-blind, randomized study. Eligibility criteria included a body mass index (BMI; in kg/[m.sup.2]) of 25-35. Body weight was measured, and dual-energy X-ray absorptiometry, indirect calorimetry (men only), and genotyping were conducted. Results: Forty women and 40 men with a mean ([+ or -] SD) age of 42 [+ or -] 8 y and BMI of 30.4 [+ or -] 2.4 were randomly assigned to a capsinoid or placebo group. Capsinoids were well tolerated. Mean ([+ or -] SD) weight change was 0.9 [+ or -] 3.1 and 0.5 [+ or -] 2.4 kg in the capsinoid and placebo groups, respectively (P = 0.86). There was no significant group difference in total change in adiposity, but abdominal adiposity decreased more (P = 0.049) in the capsinoid group (-1.11 [+ or -] 1.83%) than in the placebo group (-0.18 [+ or -] 1.94%), and this change correlated with the change in body weight (r = 0.46, P < 0.0001). Changes in resting energy expenditure did not differ significantly between groups, but fat oxidation was higher at the end of the study in the capsinoid group (least-squares mean difference: 21.0 mg/min; P = 0.06). Of 13 genetic variants tested, TRPV1 Va1585Ile and UCP2 -866 G/A correlated significantly with change in abdominal adiposity. Conclusions: Treatment with 6 mg/d capsinoids orally appeared to be safe and was associated with abdominal fat loss. Capsinoid ingestion was associated with an increase in fat oxidation that was nearly significant. We identified 2 common genetic variants that may be predictors of therapeutic response.

Details

Language :
English
ISSN :
00029165
Volume :
89
Issue :
1
Database :
Gale General OneFile
Journal :
American Journal of Clinical Nutrition
Publication Type :
Periodical
Accession number :
edsgcl.192586879